Clinical Trials Logo

Colorectal Cancer clinical trials

View clinical trials related to Colorectal Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05387876 Active, not recruiting - Colorectal Cancer Clinical Trials

Vitamin D Intervention and Associated Changes in the Gut Microbiome and Vitamin D Levels in Healthy Adults

VDMT
Start date: February 14, 2022
Phase: N/A
Study type: Interventional

Although dietary vitamin D supplementation has been used in the clinical setting for decades, the effect of supplementary vitamin D consumption on the structure of the microbiome has not been studied in humans in fine scale or with concomitant adjustment for dietary intake. Understanding the interaction of vitamin D with the microbiome in humans could lead to important advancements in the understanding of how vitamin D together with diet impacts the microbiome composition, and ultimately, risk of EOCRC. This study has the potential to lay the ground work for an adjunctive therapy to manipulate the microbiome to reduce risk of EOCRC. This proposed study is designed to evaluate the effect of vitamin D supplementation on the normal structure of the microbiome and data will not be used to diagnose, prevent, cure or treat disease.

NCT ID: NCT05348187 Active, not recruiting - Colorectal Cancer Clinical Trials

Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit

Start date: July 1, 2019
Phase: N/A
Study type: Interventional

An interventional, prospective clinical performance study protocol, for the testing of DNA extracted from tumor tissue biopsy samples, using the therascreen® KRAS RGQ PCR Kit, from patients with Non-Small Cell Lung Cancer and Colorectal Cancer, screened in Amgen's clinical trial (Protocol No. 20170543).

NCT ID: NCT05341622 Active, not recruiting - Colorectal Cancer Clinical Trials

Mailed FIT Outreach 2022

Start date: May 27, 2022
Phase: N/A
Study type: Interventional

This project aims to evaluate different approaches to increase colorectal cancer screening among primary care patients at Penn Medicine through a centralized screening outreach program. In a pragmatic trial, we will evaluate different approaches to increase response rate to mailed fecal immunochemical test (FIT) kits among eligible patients, including differentiated packaging, sending text reminders, and personalized reminders.

NCT ID: NCT05281159 Active, not recruiting - Colorectal Cancer Clinical Trials

Increasing Engagement With Messages Regarding CRC Screening Among Adults Aged 45-49

CRC45+TEXT
Start date: February 21, 2022
Phase: N/A
Study type: Interventional

In May of 2021, the United States Preventive Service Task Force (USPSTF) updated their colorectal cancer (CRC) screening guidelines by recommending screening at an earlier age for average-risk adults starting at the age of 45 years old (Grade B recommendation). This is in addition to their Grade A recommendations of continuing to screen average-risk adults ages 50-75 years old. As the investigators health system aims to screen the newly eligible population of average-risk patients between the ages of 45-49, the investigators proposed randomized controlled trial is aimed to determine the most effective patient outreach approach to increase patients' engagement with messages regarding CRC screening and screening uptake within this specific age-group.

NCT ID: NCT05275530 Active, not recruiting - Colorectal Cancer Clinical Trials

The Impact of Choice on Colorectal Cancer Screening

CRC45+
Start date: February 21, 2022
Phase: N/A
Study type: Interventional

In May of 2021, the United States Preventive Service Task Force (USPSTF) updated their colorectal cancer (CRC) screening guidelines by recommending screening at an earlier age for average-risk adults starting at the age of 45 years old (Grade B recommendation). This is in addition to their Grade A recommendations of continuing to screen average-risk adults ages 50-75 years old. UCLA Health previously implemented a fecal immunochemical test (FIT) outreach program wherein FIT kits are mailed to average-risk patients overdue for CRC screening twice annually to promote screening uptake. As the investigators health system aims to screen the newly eligible population of average-risk patients between the ages of 45-49, the investigators proposed randomized controlled trial is aimed to determine the most effective patient outreach approach to maximize screening uptake within this age-group.

NCT ID: NCT05238558 Active, not recruiting - Colorectal Cancer Clinical Trials

Safety and Immune Response to FMPV-1

Start date: January 31, 2022
Phase: Phase 1
Study type: Interventional

This is a single centre, open-label, non-randomized, Phase I study assessing safety and immune response of FMPV-1 in healthy male subjects.

NCT ID: NCT05150548 Active, not recruiting - Colorectal Cancer Clinical Trials

Predictive Time-to-Event Model for Major Medical Complications After Colectomy

Start date: December 1, 2021
Phase:
Study type: Observational

Purpose: The purpose of this study is to create prediction models for when major complications occur after elective colectomy surgery. Justification: After surgery, patients can have multiple complications. Accurate risk prediction after surgery is important for determining an appropriate level of monitoring and facilitating patient recovery at home. Objectives: Investigators aim to develop and internally validate prediction models to predict time-to-complication for each individual major medical complications (pneumonia, myocardial infarction (MI) (i.e. heart attacks), cerebral vascular event (CVA) (i.e. stroke), venous thromboembolism (VTE) (i.e. clots), acute renal failure (ARF) (i.e. kidney failure), and sepsis (i.e. severe infections)) or adverse outcomes (mortality, readmission) within 30-days after elective colectomy. Data analysis: Investigators will be analyzing a data set provided by the National Surgical Quality Improvement Program (NSQIP). Descriptive statistics will be performed. Cox proportional hazard and machine learning models will be created for each complication and outcome outlined in "Objectives". The performances of the models will be assessed and compared to each other.

NCT ID: NCT05101382 Active, not recruiting - Colorectal Cancer Clinical Trials

A Retrospective Protocol Empowering Precision Research in Colorectal Cancer (ALFAOMEGA-RETRÒ)

ALFAOMEGA-R
Start date: October 28, 2020
Phase:
Study type: Observational

ALFAOMEGA-RETRÒ will be exploited to retrospectively collect clinical and imaging data and archival samples to be used for validation and correlative studies on markers discovered by cutting-edge translational projects within the AIRC5x1000 program "Insights into the evolving heterogeneity of colorectal cancer (CRC): from mechanism to therapies" (an ongoing multi-institutional research program).

NCT ID: NCT05059717 Active, not recruiting - Clinical trials for Colorectal Carcinoma Metastatic in the Liver

An Investigational Scan (MR DENSE) in Detecting Early Chemotherapy-Related Liver Injury Before Surgery in Patients With Resectable Colorectal Liver Metastases

Start date: July 12, 2018
Phase: N/A
Study type: Interventional

This trial studies how well a magnetic resonance imaging technique called Displacement Encoding with Stimulated Echo (DENSE) works in detecting chemotherapy-related liver injury in patients with colorectal cancer that has spread to the liver and can be removed by surgery. Researchers want to learn if the DENSE technique improves the standard MRI method.

NCT ID: NCT05018156 Active, not recruiting - Colorectal Cancer Clinical Trials

Default Genetics Referrals for Young-Onset Colorectal Cancer

Start date: November 10, 2021
Phase: N/A
Study type: Interventional

The investigators will perform a pilot implementation study of a default genetics referral process among patients with young-onset CRC diagnosed between ages 40 and 49.